Olema Pharmaceuticals, Inc.
OLMANasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Operating income | −$178.7M | −$142.3M | −$105.0M | −$107.0M | −$71.5M | −$21.5M |
| Net income | −$162.5M | −$129.5M | −$96.7M | −$104.8M | −$71.1M | −$22.1M |
| Total assets | $533.4M | $451.0M | $276.9M | $215.6M | $295.9M | $342.7M |
| Total liabilities | $54.9M | $42.0M | $23.1M | $18.1M | $11.4M | $4.6M |
| Equity | $478.6M | $409.0M | $253.9M | $197.5M | $284.6M | $338.1M |
| EPS (diluted) | $-1.87 | $-2.20 | $-2.14 | $-2.62 | $-1.80 | $-3.42 |
| Shares out. | 68.3M | 55.9M | 40.6M | 40.3M | 39.8M | 39.3M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −33.9%
- Return on assets
- −30.5%
- Return on capital (ROCE)
- −37.1%
- Liabilities / assets
- 10.3%
- Debt / equity
- 0.11×
- Book value / share
- $7.00
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 8.96safe
- Accruals / assets
- −2.9%clean
- Piotroski F-Score
- 1/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 warning● 3 good- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1Active Not Recruitingreadout ~2026-03A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients
- Phase 3Recruitingreadout ~2026-06-30OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
- Phase 1Recruitingreadout ~2027-05-30Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
- Phase 1Recruitingreadout ~2027-12-31Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
- Phase 3Recruitingreadout ~2028-12Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Janus Henderson Group PlcPassive (13G)May 15, 2026
- Bain Capital Life Sciences Opportunities Iv, L.P.Passive (13G)May 15, 2026
- Invus Global Management, LlcPassive (13G)Mar 20, 2026
- Fmr LlcPassive (13G)Mar 6, 2026
- Deep Track Capital, LpPassive (13G)Feb 13, 2026
- Point72 Asset Management, L.P.Passive (13G)May 15, 2025
- Logos Global Management LpActivist (13D)May 13, 2025
- Paradigm Biocapital Advisors LpPassive (13G)Feb 14, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Mitchell ShawnteOfficer — CHIEF LEGAL OFFICER | Mar 3, 2026 | Option exercise | 15,000 | $4.37 |
| Austin Sasha LuOfficer — VP of Finance and Controller | Feb 2, 2026 | Grant | 11,700 | $0.00 |
| Harmon CyrusDirector | Jan 20, 2026 | Sell | 10,000 | $26.88 |
| Harmon CyrusDirector | Jan 14, 2026 | Sell | 3,489 | $29.12 |
| Kovacs Shane William CharlesOfficer — CH. OPERATING & FINANCIAL OFF. | Jan 13, 2026 | Sell | 3,822 | $28.01 |
| Myles David C.Officer — CH. DISCOV. & NON-CLIN DEV OFF | Jan 12, 2026 | Sell | 10,000 | $28.34 |
| Bohen SeanOfficer — President and CEO | Dec 26, 2025 | Gift | 8,500 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 11.6M | 10.2 | -11.2% |
| Apr 30, 2026 | 13.0M | 16.5 | +0.8% |
| Apr 15, 2026 | 12.9M | 14.6 | +5.5% |
| Mar 31, 2026 | 12.3M | 6.3 | +48.8% |
| Mar 13, 2026 | 8.2M | 3.0 | -0.2% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Regulation FD disclosure · Other material eventMay 26, 2026
- Regulation FD disclosure · Other material eventMay 21, 2026
- Results of operationsMay 12, 2026
- Entered a material agreement · New financial obligationMay 1, 2026
- Director / officer change · Regulation FD disclosureApr 29, 2026
- Results of operationsMar 16, 2026
- Director / officer changeJan 30, 2026
- Results of operations · Regulation FD disclosureJan 12, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 8-KMay 26, 2026
- 8-KMay 21, 2026
- SCHEDULE 13G/AMay 15, 2026
- SCHEDULE 13G/AMay 15, 2026
- 10-QMay 12, 2026
- 8-KMay 12, 2026
- 8-KMay 1, 2026
- 4Apr 29, 2026
- 3Apr 29, 2026
- ARSApr 29, 2026
- DEFA14AApr 29, 2026
- DEF 14AApr 29, 2026
- 8-KApr 29, 2026
- SCHEDULE 13GMar 20, 2026
- 144Mar 16, 2026
Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.